|
|
||||
| Email This Page to Friend | |||||
|
Breast Cancer News
|
||||
|
by AP 2 Sep 2010 at 3:01am Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug. by Reuters 2 Sep 2010 at 6:20am A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market. by HealthDay 2 Sep 2010 at 8:03am THURSDAY, Sept. 2 (HealthDay News) -- Many Americans have skewed perceptions when it comes to their weight, often believing they are lighter than they actually are, even when the scales are shouting otherwise, a new poll finds. by Reuters 2 Sep 2010 at 6:19am While staying mentally active in old age has been linked to a delayed onset of dementia, seniors who engage in such brain "exercise" may actually have a faster rate of decline once Alzheimer's is diagnosed, researchers reported Wedne... by AFP 2 Sep 2010 at 4:27am The chief of the UNAIDS agency said Thursday that global contributions to fighting the disease are dropping off for the first time in 15 years amid tough economic times. by Reuters 2 Sep 2010 at 11:21am Companies are cutting healthcare costs further amid a continuing sour economy, scaling back benefits and shifting a greater share of the expense to employees. by Reuters 2 Sep 2010 at 10:35am The estrogen-like compounds found in soy could help postmenopausal women get a better night's sleep, according to a small study. by Reuters 2 Sep 2010 at 12:19pm Women who start menstruating early may be at increased risk of asthma and poor lung function, new research shows. by Reuters 2 Sep 2010 at 2:33pm A cell phone text message -- and the buzz or beep that signals its arrival -- may not help a woman remember to pop her birth control pill, a new study suggests. by AFP 2 Sep 2010 at 1:05pm Researchers have discovered a promising new malaria drug with the potential to treat resistant strains of the deadly disease in a single dose, according to a study published Thursday in the journal Science. by Reuters 2 Sep 2010 at 2:38pm Pakistan's displaced flood victims say a lack of clean water and high temperatures are causing illnesses sweeping through relief camps with children most at risk. by Reuters 2 Sep 2010 at 1:54pm An experimental Novartis drug can clear malaria infection in mice with a single dose and scientists say it shows promise as a possible future treatment for one of the world's major killer diseases. by AFP 2 Sep 2010 at 2:16pm A groundbreaking new test can accurately diagnose drug-resistant tuberculosis (TB) in as little as two hours, researchers wrote in a study published Thursday in the New England Journal of Medicine. by Reuters 2 Sep 2010 at 1:46pm When it comes to changing health behaviors, it takes more than a far-flung network of friends on Facebook egging you on. It takes a jostling herd, U.S. researchers said on Thursday. by Reuters 2 Sep 2010 at 2:30pm A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market. |
12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 12 Jan 2009 at 6:24am 25 Sep 2007 at 10:41pm 25 Sep 2007 at 10:41pm 25 Sep 2007 at 10:41pm 25 Sep 2007 at 10:41pm 25 Sep 2007 at 10:41pm As you are aware we are the leading publishers of health news on the web. We publish news items in various forms including numerous blogs and news items. We invite you to participate in our new collection. We are looking for quality news items that would be interesting to our readers. Now you may suggest the news item from your site to be included at Medicineworld.org. Inclusion of news item at our site get instantaneous attention since the item is illustrated from various blog posts. Addition of pictures to the item adds additional attraction to your news item. Inclusion in the Medicineworld.org site brings quality links and visitors to your site........ 25 Sep 2007 at 10:41pm Medicineworld wishes all our readers merry Christmas. Oh, jingle bells, jingle bells Jingle all the way...... 25 Sep 2007 at 10:41pm Emory Winship Cancer Institute is the only cancer research and treatment facility in Georgia to offer an innovative Phase II clinical trial for transitional cell carcinoma (TCC), a common form of bladder cancer. The clinical trial is testing the efficacy of the investigational drug Vinflunine. Vasily Assikis, MD, assistant professor of hematology and oncology and director of Winship's Prostate Cancer Translational Research Program is principal investigator....... 25 Sep 2007 at 10:41pm A new population-based study has found that patients 75 years of age or older with invasive bladder cancer are less likely to receive the recommended surgical treatment for the disease.The findings "suggest in a sense some undertreatment of our older patients," Dr. Brenda K. Edwards of the National Cancer Institute, Bethesda, Maryland, told Reuters Health. However, she noted, the study was unable to gauge the influence of factors such as patient choice, which also could have made surgery less common among older patients....... 25 Sep 2007 at 10:41pm Previous research from Ohio State and Harvard Universities showed that men who ate broccoli had half the risk of bladder cancer compared to those who did not. Now the researchers have isolated interesting compounds from broccoli sprouts. Known as glucosinolates, they are turned into isothiocyanates during chopping, chewing and digestion. Experiments with bladder cancer cells, including the most aggressive type, shows that the isothiocyanates can block their growth. The scientist believe there may be up to a dozen other compounds in broccoli that have a similar effect....... |
31 Aug 2010 at 10:47am Researchers say tens of thousands of women could avoid getting breast cancer each year if they got more gentle exercise in--particularly walking. 30 Aug 2010 at 3:40pm Scientists at Oxford University have discovered a link between vitamin D deficiency and genes related to both cancer and autoimmune diseases. 30 Aug 2010 at 3:11pm Drugs on the list include the birth control pill Inplanon, the breast cancer drug Herceptin, and the heart drug Multaq. 16 Aug 2010 at 9:54am A new study may reignite the debate on the risks posed by hormone replacement therapy (HRT) on breast cancer. 26 Jul 2010 at 12:14pm An advisory panel to the U.S. Food and Drug Administration has overwhelmingly voted to withdrawal approval for the breast cancer drug Avastin. 26 Jul 2010 at 12:05pm Women with African heritage are more prone to the deadlier "triple negative" type of breast cancer, researchers say. 12 Jul 2010 at 11:14am In the 1970s 44 percent of women diagnosed with breast cancer survived for at least 10 years, compared to 77 percent now. 12 Jul 2010 at 10:07am Seattle researchers followed over 35,000 post-menopausal women and found that those who regularly took a fish oil supplement had a 32 percent reduced risk of developing the most common form of breast cancer. 30 Jun 2010 at 2:55pm According to the Center for Science in the Public Interest (CSPI), food dyes commonly used in foods from cereals and candy to fruit drinks may cause hyperactivity, allergic reactions, and even cancer. 29 Jun 2010 at 11:45am Researchers say troublesome side effects keep many women from refilling their prescriptions for the recommended five-year period. 29 Jun 2010 at 11:43am Experts are urging cancer patients to exercise more in order to reduce fatigue and stave off physical changes that can last years. 25 Jun 2010 at 11:33am Women who take oral bisphosphonates for osteoporosis appear to have a reduced risk of some breast cancers, a new study has found. 21 Jun 2010 at 3:54pm Women who underwent psychological intervention during an initial bout of breast cancer handled the stress of recurrence and even had longer survival rates than their peers, a new study has found. 21 Jun 2010 at 3:43pm A blood test that can detect breast cancer up to a year in advance could dramatically improve survival rates, researchers say. 16 Jun 2010 at 6:36pm According to a new study, cancer survivors who do yoga sleep better, experience less fatigue, and have a slightly increased quality of life. |
by Aleix Prat 1 Sep 2010 at 7:00pm IntroductionIn breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. Methods: The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets. These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models. Results: Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features. Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell. Conclusions: These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines. by Yubo Chai 31 Aug 2010 at 7:00pm IntroductionNatural herbal compounds with novel actions different from existing breast cancer (BCa) treatment modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-O-galloyl-beta-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through inhibiting DNA replicative synthesis and G1 arrest, in addition to inducing cell death at higher levels of exposure. We and others have shown that PGG through intraperitoneal (i.p.) injection exerts a strong in vivo growth suppression of human PCa xenograft models in athymic nude mice. This study aims to test the hypothesis that the novel targeting actions of PGG are applicable to BCa cells, especially those lacking proven druggable targets. Methods: Mono-layer cell culture models of p53-wild type estrogen receptor (ER)-dependent MCF-7 BCa cells and p53-mutant ER-/progesterone receptor (PR)- and Her2-regular (triple-negative) MDA-MB-231 BCa were exposed to PGG for a comprehensive investigation of cellular consequences and molecular targets/mediators. To test the in vivo efficacy, female athymic mice inoculated with MDA-MB-231 xenograft were treated with 20mg PGG/kg body weight by daily gavage starting 4 days after cancer cell inoculation. Results: Exposure to PGG induced S-phase arrest in both cell lines as indicated by the lack of 5-bromo2'-deoxy-uridine (BrdU) incorporation into S-phase cells as well as G1 arrest. Higher levels of PGG induced more caspase-mediated apoptosis in MCF-7, in strong association with induction of P53 Ser15 phosphorylation, than in MDA-MB-231 cells. The cell cycle arrests were achieved without an induction of cyclin dependent kinase (CDK) inhibitory proteins P21Cip1 and P27Kip1. PGG treatment led to decreased cyclin D1 in both cell lines and over-expressing cyclin D1 attenuated G1 arrest and hastened S arrest. In serum-starvation synchronized MCF-7 cells, down-regulation of cyclin D1 was associated with de-phosphorylation of retinoblastoma (Rb) protein by PGG shortly before G1-S transition. In vivo, oral administration of PGG led to a greater than 60% inhibition of MDA-MB231 xenograft growth without adverse effect on host body weight. Conclusions: Our in vitro and in vivo data support PGG as a potential drug candidate for breast cancer with novel targeting actions, especially for a triple negative BCa xenograft model. by Fabio Parisi 31 Aug 2010 at 7:00pm IntroductionMulti-marker molecular assays have impacted management of early stage breast cancer, facilitating adjuvant chemotherapy decisions. We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction. Methods: We used a quantitative immunofluorescence method to study protein expression of 14 markers included in the Oncotype DXTM assay on a 638 breast cancer patient cohort with 15-year follow-up. We performed cross-validation analyses to assess performance of multivariate Cox models consisting of these markers and standard clinico-pathological covariates, using an average time-dependent Area Under the Receiver Operating Characteristic curve and compared it to nested Cox models obtained by robust backward selection procedures. Results: A prognostic index derived from a multivariate Cox regression model incorporating molecular and clinico-pathological covariates (nodal status, tumor size, nuclear grade, and age) is superior to models based on molecular studies alone or clinico-pathological covariates alone. Performance of this composite model can be further improved using feature selection techniques to prune variables. When stratifying patients by Nottingham Prognostic Index (NPI), most prognostic markers in high and low NPI groups differed. Similarly, for the node-negative, hormone receptor-positive sub-population, we derived a compact model with three clinico-pathological variables and two protein markers that was superior to the full model. Conclusions: Prognostic models that include both molecular and clinico-pathological covariates can be more accurate than models based on either set of features alone. Furthermore, feature selection can decrease the number of molecular variables needed to predict outcome, potentially resulting in less expensive assays. by Christine Watson 30 Aug 2010 at 7:00pm Cancer vaccines are the holy grail for patients and clinicians alike. The possibility that we can be vaccinated against common cancers is very appealing and the socio-economic consequences significant. A recent paper from Vincent Tuohy's group, published in the journal Nature Medicine, suggests a new approach for the development of a prophylactic vaccine for breast cancer. Their strategy was to induce mammary gland failure in mice by immunization with an antibody specific to a milk protein that resulted in autoimmunity during lactation. This also showed some efficacy as a therapeutic vaccine. Can we look forward to the elimination of breast cancer? by Diana Cittelly 30 Aug 2010 at 7:00pm The vital role of ovarian hormones in the development of normal breast foreshadowed their importance in mammary stem cell regulation. Two recent papers reveal that 17-beta-estradiol and progesterone control the size and repopulating ability of the mammary stem cell compartment. This likely occurs via paracrine signaling from steroid receptor positive luminal cells to steroid receptor negative stem cells. These findings illuminate roles for the female sex steroids in mobilizing the stem cell pool in the normal breast, and also provide a crucial link between the known hormonal risks of breast cancer and the potential stem cell origin of this disease. by Vilde Haakensen 26 Aug 2010 at 7:00pm IntroductionMammographic density (MD), as assessed from film screen mammograms, is determined by the relative content of adipose, connective and epithelial tissue in the female breast. In epidemiological studies, a high percentage of MD confers a four to six fold risk elevation of developing breast cancer, even after adjustment for other known breast cancer risk factors. However, the biologic correlates of density are little known. Methods: Gene expression analysis using whole genome arrays was performed on breast biopsies from 143 women; 79 women with no malignancy (healthy women) and 64 newly diagnosed breast cancer patients, both included from mammographic centres. Percent MD was determined using a previously validated, computerized method on scanned mammograms. Significance analysis of microarrays (SAM) was performed to identify genes influencing MD and a linear regression model was used to assess the independent contribution from different variables to MD. Results: SAM-analysis identified 24 genes differentially expressed between samples from breasts with high and low MD. These genes included three uridine 5'-diphospho-glucuronosyltransferase (UGT) genes and the oestrogen receptor gene (ESR1). These genes were down-regulated in samples with high MD compared to those with low MD. The UGT gene products, which are known to inactivate oestrogen metabolites, were also down-regulated in tumour samples compared to samples from healthy individuals. Several single nucleotide polymorphisms (SNPs) in the UGT genes associated with the expression of UGT and other genes in their vicinity were identified. Conclusions: Three UGT enzymes were lower expressed both in breast tissue biopsies from healthy women with high MD and in biopsies from newly diagnosed breast cancers. The association was strongest amongst young women and women using hormonal therapy. UGT2B10 predicts MD independently of age, hormone therapy and parity. Our results indicate that down-regulation of UGT genes in women exposed to female sex hormones is associated with high MD and might increase the risk of breast cancer. by Jean Abraham 22 Aug 2010 at 7:00pm IntroductionTamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from published studies evaluating CYP2D6 variants as predictive factors of tamoxifen efficacy and clinical outcome are conflicting, querying the clinical utility of CYP2D6 testing. We investigated the association of CYP2D6 variants with breast cancer specific survival (BCSS) in breast cancer patients receiving tamoxifen. Methods: This was a population based case-cohort study. We genotyped known functional variants (n=7; minor allele frequency (MAF)>0.01) and single nucleotide polymorphisms (SNPs) (n=5; MAF>0.05) tagging all known common variants (tagSNPs), in CYP2D6 in 6640 DNA samples from patients with invasive breast cancer from the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity); 3155 cases had received tamoxifen therapy. There were 312 deaths from breast cancer, in the tamoxifen treated patients, with over 18000 years of cumulative follow-up. The association between genotype and BCSS was evaluated using Cox proportional hazards regression analysis. Results: In tamoxifen treated patients, there was weak evidence that the poor-metaboliser variant, CYP2D6*6, (MAF=0.01), was associated with decreased BCSS (P=0.02; HR=1.95; 95% CI=1.12-3.40). No other variants, including CYP2D6*4 (MAF=0.20), previously reported to be associated with poorer clinical outcomes, were associated with differences in BCSS, in either the tamoxifen or non-tamoxifen groups. Conclusions: CYP2D6*6 may affect BCSS in tamoxifen-treated patients. However, the absence of an association with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association between CYP2D6 genotype and treatment response in breast cancer. Until larger, prospective studies confirming any associations are available, routine CYP2D6 genetic testing should not be used in the clinical setting. by Stefania Gastaldi 22 Aug 2010 at 7:00pm Recent findings suggest the involvement of the MET oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor, in the onset and progression of basal-like breast carcinoma. The expression profiles of basal-like tumors - but not those of other breast cancer subtypes - are enriched for gene sets that are coordinately over-represented in transcriptional signatures regulated by Met. Consistently, tissue microarray analyses have revealed that Met immunoreactivity is much higher in basal-like cases of human breast cancer than in other tumor types. Finally, mouse models expressing mutationally activated forms of Met develop a high incidence of mammary tumors, some of which exhibit basal characteristics. The present review summarizes current knowledge on the role and activity of Met in basal-like breast cancer, with a special emphasis on the correlation between this tumor subtype and the cellular hierarchy of the normal mammary gland. by Marija Plodinec 22 Aug 2010 at 7:00pm Cells constantly encounter physical forces and respond to neighbors and circulating factors by triggering intracellular signaling cascades that in turn affect their behavior. The mechanisms by which cells transduce mechanical signals to downstream biochemical changes are not well understood. In their work, Salaita and coworkers show that the spatial organization of cell surface receptors is crucial for mechanotransduction. Consequently, force modulation that disrupts the mechanochemical coupling may represent a critical step in cancerogenesis. by Jingqin Luo 19 Aug 2010 at 7:00pm Microarray data have been widely utilized to discover biomarkers predictive of response to endocrine therapy in estrogen receptor-positive breast cancer. Typically, these data have focused on analyses conducted on the diagnostic specimen. However, dynamic temporal changes in gene expression associated with treatment may deliver significant improvements to the current generation of predictive models. We present and discuss some statistical issues relevant to the paper by Taylor and colleagues, who conducted studies to model the prognostic potential of gene expression changes that occur after endocrine treatment. |
2 Sep 2010 at 7:00am A study published in the Journal of the American Medical Association suggests that women with a gene mutation linked to breast and ovarian cancer face lower risks of developing such cancer after receiving mastectomies or having their ovaries removed, The Wall Street Journal reports... 2 Sep 2010 at 6:00am Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training... 2 Sep 2010 at 5:00am Specific prevention and education strategies are needed to address breast cancer in Mexican-origin women in this country, according to a study at The University of Texas MD Anderson Cancer Center, which was published online in the journal Cancer... 2 Sep 2010 at 5:00am Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study... 2 Sep 2010 at 3:00am When breast cancer surgeons regularly confer with plastic surgeons prior to surgery, their patients are more likely to have reconstruction, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Where a woman goes for breast cancer treatment can vary widely - ranging from small private practices to large hospital settings... 2 Sep 2010 at 3:00am The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate.... 1 Sep 2010 at 8:00am Eisai Inc. announced today that it has received notification from the U.S... 1 Sep 2010 at 7:00am Girls eating a high-fat diet during puberty, even those who do not become overweight or obese, may be at a greater risk of developing breast cancer later in life, according to Michigan State University researchers. The implications - that a high-fat diet may have detrimental effects independent of its effect to cause obesity - could drive new cancer prevention efforts... 1 Sep 2010 at 5:00am A 51-year-old breast cancer patient from Switzerland has become the first person in the world to be treated using Gated RapidArcĀ®, which makes it possible to monitor patient breathing and compensate for tumor motion while quickly delivering radiotherapy during a continuous rotation around the patient... 1 Sep 2010 at 3:00am Women with the inherited mutations of the BRCA1 or BRCA2 genes who had preventive (prophylactic) breast removal (mastectomy) or the removal of the fallopian tubes and ovaries (salpingo-oophorectomy) were found to have a significantly lower risk of developing ovarian and breast cancers, says a study published in JAMA (Journal of the American Medical Association), September 1st issue... 31 Aug 2010 at 6:00am ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, announced that Genentech, a member of the Roche Group, announced its receipt of a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for the accelerated approval of the Biologic License Application (BLA) for trastuzumab-DM1, or T-DM1, submitted in July 2010... 31 Aug 2010 at 5:00am For the first time, researchers at Fred Hutchinson Cancer Research Center have identified and isolated adult mammary stem cells in mice. Long-term implications of this research may include the use of such cells to regenerate breast tissue, provide a better understanding of the role of adult stem cells in breast cancer development, and develop potential new targets for anti-cancer drugs... 30 Aug 2010 at 4:00am AARP Bulletin: "Two years after undergoing a double mastectomy and chemotherapy so severe she was hospitalized in intensive care for several weeks, breast cancer survivor Denise Hicks should be following what her doctors call 'the plan,'" which includes additional medications and treatments. But she can't. "Hicks has health insurance but already reached her coverage limits... 29 Aug 2010 at 2:00am Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned, Genentech will continue with its ongoing Phase III registrational T-DM1 trial, EMILIA... 28 Aug 2010 at 10:00am A new test has been developed which can predict whether a breast cancer patient will respond to chemotherapy within 24-hours of starting treatment, thus sparing her unnecessary treatment and side effects, according to a study published in the medical journal Clinical Cancer Research... |
|
All information in this site is deemed reliable but not guaranteed. Garypedia.com web site owner shall
not be responsible for any typographical errors, misinformation, and misprints and shall be held totally harmless individually.Garypedia.com is an independent provider of links to news articles. Garypedia.com contains links to sites on the internet which are owned and operated by the "External Sites". Garypedia.com is not responsible for the availability of any External Sites. Contact the site administrator or Webmaster for those External Sites if you have any concerns regarding such links or the links located on such External Sites. Garypedia.com is entirely committed to protecting the privacy of its mediapartners and their users. We use a browser feature known as a cookie. One way our cookies are useful is that they help to improve and personalize your experience by increasing a page's responsiveness and decreasing time between downloading as you browse or surf through the site. Additionally, a pixel tag is delivered with the newsfeeds themselves to organize information about online activity as a means to create anonymous profiles that reflect content preferences. No personally identifiable information is stored or collected. Any suggestions, please email us.
Copyright © 2007 Garypedia.com. All rights reserved. |